Annexon (ANNX) vs Ginkgo Bioworks (DNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Annexon (ANNX) has outperformed Ginkgo Bioworks (DNA) over the past year, gaining 30.6% versus a loss of 22.6%. Over five years, ANNX leads with a -81.8% price change compared with -97.6% for DNA. Annexon is the larger company by market cap ($754.5 million vs $752.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | DNA |
|---|---|---|
| Share price | $3.98 | $11.18 |
| Market cap | $754.52M | $752.86M |
| 1-day change | -0.75% | -2.53% |
| YTD return | -20.12% | +38.03% |
| 1-year return | +30.62% | -22.60% |
| 5-year return | -81.77% | -97.59% |
| EPS (TTM) | $-1.13 | $-5.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.18 | $18.22 |
| 52-week low | $2.54 | $5.37 |
| Distance from 52-week high | -44.57% | -38.64% |
| Analyst consensus | buy | none |
| Avg. price target upside | +287.69% | -37.39% |
| Average volume | 3.11M | 1.77M |
| Shares outstanding | 189.58M | 55.38M |
| Employees | 92 | 485 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANNX has outperformed DNA by 53.2 percentage points over the past year.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees
ANNX vs DNA FAQ
Which is bigger, Annexon or Ginkgo Bioworks?
Annexon (ANNX) is larger, with a market capitalization of $754.52M compared with $752.86M for Ginkgo Bioworks (DNA).
Which stock has performed better over the past year, ANNX or DNA?
ANNX returned +30.62% over the past 12 months, compared with -22.60% for DNA (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and Ginkgo Bioworks in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Annexon and Biotechnology: Biological Products (No Diagnostic Substances) for Ginkgo Bioworks.